Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 225-004-1 | CAS number: 4602-84-0
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- dermal absorption in vitro / ex vivo
- Remarks:
- Including in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- test procedure in accordance with generally accepted scientific standards and described in sufficient detail
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- Dermal absorption of farnesol was investigated in guinea pigs in an in vivo test using radiolabelled material and also in an in vitro study by mounting skin grafts in diffusion cells and measuring receptor fluid fractions.
- GLP compliance:
- no
- Radiolabelling:
- yes
- Remarks:
- Radiochemical purity greater than 99% and a specific activity of 20.0 mCi/mmol
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Housing: Single
- Individual metabolism cages: polycarbonate shoe box cages on hardwood chip contact bedding
- Diet: ad libitum pelleted guinea pig chow
- Water: ad libitum
- Acclimation period: 3-days in quarantine
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21±1°C
- Humidity (%): 50±10 % relative humidity
- Air changes (per hr): 10 complete room changes per hour
- Photoperiod (hrs dark / hrs light): 12 hours light/dark full spectrum lighting cycle (no twilight) - Type of coverage:
- occlusive
- Vehicle:
- other: oil-in-water emulsion prepared with: 3% polyglycerate distearate; 3% cetyl stearyl alcohol; 10% light mineral oil; 5% propylene glycol; 0.5% propyl-p-hydroxybenzoate; 0.5% methyl-p-hydroxybenzoate and 78% water
- Doses:
- An oil-in-water emulsion containing 5.0% of unlabelled farnesol, spiked with 3H-farnesol so that approximately 0.5 µCi of radiolabelled farnesol was applied per cm2 of skin in vivo or to the skin in vitro diffusion cell. The emulsion was applied to the skin at a dosage of 1 mg/cm2.
- No. of animals per group:
- 3
- Control animals:
- no
- Details on study design:
- In vivo skin absorption study - A 3.0 x 3.0 cm treatment site was marked on the mid-scapular region of the guinea pig’s back and enclosed with a Stomahesive® patch glued directly to the animal’s skin, the dosing area and patch were then covered with a vinyl coated fibreglass screen (to prevent dosing formulation being rubbed off the skin) and carbon impregnated filter paper to trap volatile test material. In vivo skin absorption was determined 24-hours after dosing. Urine and faeces were collected throughout the study duration. Animals were euthanized with Isoflurane. The skin at the treatment site, ovaries, liver and kidneys were excised and dissoluted in potassium hydroxide (5M). Radioactivity was measured by liquid scintillation counting.
- Details on in vitro test system (if applicable):
- Skin grafts (200-300 µm thick) were obtained from hairless guinea pigs euthanized with carbon dioxide. The skin was washed with 1% (v/v) liquid detergent solution, rinsed with distilled water and patted dry. Diffusion cells (0.64 cm2) and the perfusion system were prepared and flushed with 70% (v/v) ethanol solution and the receptor fluid was sterilised by vacuum filtration through a 0.2 µm filter. The skin was mounted in the diffusion cell and equilibrated to the test conditions (1.5 ml/hour) and the dosing was applied to the surface, in a manner comparable to the in vivo tests (oil-in-water emulsion). Receptor fluid fractions were collected at 6-hour intervals for 24-72 hours.
- Signs and symptoms of toxicity:
- not examined
- Dermal irritation:
- not examined
- Absorption in different matrices:
- In vivo absorption of farnesol in three animals, 24 hours after dermal application, resulted in systematic absorption of 39.8±2.5 %AD (mean ± SEM) percent of the applied dose (% AD). At 24-hours, 2.1±0.2 %AD of farnesol remained in the skin and 5.0±2.2 %AD was extracted from carbon impregnated filter papers. The total penetration (systemically absorbed + skin absorption + recovery of materials in skin around the dosing site) corresponded to 44.1 ± 2.2% AD, 5.4 ± 1.3%AD was recovered in the urine. The total recovery (mass balance) corresponded to 65.9 ± 6%.
Twenty-four hour in vitro absorption studies suggested total penetration of farnesol to be 69.9±4.3 %AD, with 43.5 ± 3.3%AD in the receptor fluid, with 26.4 ± 4.1%AD remaining in the skin (approximately 19.2 ± 4.6%AD in the viable skin and 7.2 ± 1.3%AD in the stratum corneum). Extended 72-hour studies found 77.5±4.7 %AD in the receptor fluid with 8.0±1.9 %AD remaining in the skin (approximately 2.8 ± 0.7%AD in the viable skin and 5.2 ± 1.2%AD in the stratum corneum). The total 72-hour in vitro penetration of farnesol was calculated to be 85.5±6.7 %AD. The total recovery was 105.8 ± 6.2% at 72 h. - Total recovery:
- The systemic in vivo absorption value coincided with the 24 -hour in vitro absorption value. However, the evaporation test for 3H-Farnesol suggested that there is a potential for evaporative loss.
- Conclusions:
- As a lipophilic compound, farnesol has been shown to be readily absorbed and distributed in Hartley guinea pigs in vitro and in vivo.
- Executive summary:
The dermal absorption of farnesol was investigated in Hartley guinea pigs in vivo using radiolabelled material and in vitro by mounting skin grafts in diffusion cells and measuring receptor fluid fractions. Comparable in vitro and in vivo dermal absorption of farnesol was observed. The in vivo absorption of farnesol led to systematic absorption of 39.8±2.5 % of the applied dose (AD) (mean ± SEM). At 24-hours, 2.1±0.2 %AD of farnesol remained in the skin and 5.0±2.2 %AD was extracted from carbon impregnated filter papers. In vitro farnesol absorption studies suggested penetration of 69.9±4.3 %AD. Extended 72-hour studies found 77.5±4.7 %AD in the receptor fluid with 8.0±1.9 %AD remaining in the skin. The total 72-hour in vitro penetration of farnesol was calculated to be 85.5±6.7 %AD. Under the experimental conditions stated, farnesol is readily absorbed and systemically distributed. This study is considered to be reliable without restriction (Klimisch 1) as it was a published study with adequate experimental design and sufficient reporting.
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
- Remarks:
- The study was not of guideline design including just two treatment groups and a control, and was not conducted to GLP
- Objective of study:
- absorption
- metabolism
- Qualifier:
- no guideline followed
- Principles of method if other than guideline:
- The study design was similar to an OECD 407 28-day repeated dose toxicity study although only two treated groups were included together with a standard vehicle control group. The numbers of animals per group complied with guideline requirements for studies of this type along with the experimental conditions. Half the animals from each group were terminated after 28 days of oral dosing whilst the remaining animals were terminated after a further 28-day period without treatment to assess recovery from any toxicities. Blood samples were taken from all animals at termination for the determination of plasma farnesol levels.
- GLP compliance:
- not specified
- Radiolabelling:
- no
- Species:
- rat
- Strain:
- Sprague-Dawley
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- Rats were individually housed in stainless steel cages suspended over absorbent cage boards, and were held in a temperature-controlled room maintained on a 12 h light/dark cycle. Rats were permitted free access to drinking water (supplied by automatic watering system) at all times during the study; rats were also allowed free access to Purina Certified Rodent Diet 5002 (PMI Nutrition International Inc., Brentwood, MO) throughout the study, except during an overnight fast prior to scheduled necropsies.
- Route of administration:
- oral: gavage
- Vehicle:
- corn oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- Dose levels of 500 or 1000 mg/kg/day were selected on the basis of a previous pre-clinical 28-day toxicity study without recovery
VEHICLE
- Justification for use and choice of vehicle (if other than water): Not stated
- Concentration in vehicle: Not stated
- Amount of vehicle (if gavage): 5 mL/Kg
- Lot/batch no. (if required): Not stated
- Purity: Not stated - Duration and frequency of treatment / exposure:
- 28 days followed by a 28-day recovery period
- Dose / conc.:
- 100 other: mg/mL
- Dose / conc.:
- 200 other: mg/mL
- No. of animals per sex per dose / concentration:
- 20 male and 20 female rats per group
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Dose levels of 500 and 1000 mg/kg/day were selected by the National Cancer Institute on the basis of a previous preclinical 28-day toxicity study
- Rationale for animal assignment (if not random): animals randomly assigned to groups
- Rationale for selecting satellite groups: not stated
- Post-exposure recovery period in satellite groups: 28-day recovery period - Details on dosing and sampling:
- PHARMACOKINETIC STUDY
- Tissues and body fluids sampled: plasma
- Time and frequency of sampling: Blood samples taken from all animals killed at the end of 28-days of treatment
- Method type(s) for identification: Gas chromoatography/mass spectrometry
- Limits of detection and quantification: cis, cis-farnesol (0.233 umol/l); cis, trans-farnesol (0.527 umol/l); trans, cis-farnesol (0.516 umol/l); trans,
trans-farnesol (0.814 umol/l). - Type:
- absorption
- Results:
- Plasma levels of total farnesol and individual farnesol isomers in rats receiving daily exposure to farnesol at doses of 500 or 1000 mg/kg/day
- Details on absorption:
- Total plasma farnesol levels, and plasma levels of individual farnesol isomers in samples collected from study animals at approximately two hours post-dosing during the final week of farnesol administration are summarised in Table 1. As expected, plasma levels of total farnesol (all isomers) and individual farnesol isomers increased with increasing farnesol dose. Despite the fact that farnesol is an endogenous compound, plasma farnesol levels were not detectable in all animals in the vehicle control group (data not shown) as the levels were probably below the detection limit of the assay.
- Conclusions:
- Plasma concentrations of farnesol and associated isomers increased with increasing dose concentration following oral exposure in rats.
- Executive summary:
Male and female rats received daily exposure to farnesol at doses of 500 or 1000 mg/kg/day, alongside a vehicle control, for 28 days followed by a 28-day recovery period. Total plasma farnesol levels and plasma levels of individual farnesol isomers were analysed at approximately two hours post-dosing during the final week of farnesol administration. Plasma levels of total farnesol (all isomers) and individual farnesol isomers increased with increasing farnesol dose. This study is considered to be reliable with restriction (Klimisch 2) as it was a published study conducted similar to an OECD 407 28-day repeated dose toxicity study, with minor limitations in reporting.
Referenceopen allclose all
Table 1 - Plasma levels of total farnesol and individual farnesol isomers in rats receiving daily exposure to farnesol at doses of 500 or 1000 mg/kg/day
|
|
Concentration (µmol/L) |
|||
Male, 500a |
Male, 1000a |
Female, 500a |
Female, 1000a |
||
Total Farnesol |
Mean±SDb Rangec Nd |
3.75±2.02 1.29-6.68 8 |
7.82±1.60 5.12-9.64 10 |
5.89±3.38 2.76-11.3 9 |
8.75±2.91 5.74-13.6 10 |
cis,cisFarnesol |
Mean±SDb Rangec Nd |
0.676±0.267 0.283-0.931 5 |
1.09±0.393 0.603-1.57 10 |
0.485±0.178 0.234-0.729 5 |
0.929±0.336 0.576-1.57 10 |
cis,transFarnesol |
Mean±SDb Rangec Nd |
0.801 0.801 1 |
1.28±0.714 0.553-2.17 4 |
2.01 2.01 1 |
1.01±0.183 0.881-1.14 2 |
trans,cisFarnesol |
Mean±SDb Rangec Nd |
0.846±0.197 0.06-0.985 2 |
0.814±0.339 0.522-1.25 8 |
1.03±0.409 0.742-1.32 2 |
0.665±0.089 0.562-0.765 5 |
trans,transFarnesol |
Mean±SDb Rangec Nd |
3.02±1.44 1.29-4.95 8 |
5.57±1.00 4.08-6.97 10 |
5.18±2.64 2.76-10.0 9 |
7.29±2.27 4.90-11.6 10 |
Blood samples were collected approximately 2h post-dosing during the fourth week of farnesol administration. Plasma farnesol levels in all samples collected from vehicle controls were not detectable
a Sex and dose (mg/kg/day)
b Mean concentration (+/- standard deviation) for animals with quantifiable levels within the group
c Concentration range among animals with quantifiable levels within the group
d Number of animals (out of 10) with quantifiable levels within the group
Description of key information
The in vivo absorption of farnesol led to systematic absorption of 39.8±2.5 % of the applied dose (mean ± SEM) in Harley guinea pigs. As the total recovery (mass balance) corresponded only to 65.9 ± 6%, in vitro information was used as key information. Here, the total recovery corresponded to 105.8 ± 6.2% at 72 h and the in vitro absorption of farnesol was 85.5%. Under the experimental conditions of the test, farnesol is readily absorbed and systemically distributed.
Key value for chemical safety assessment
- Absorption rate - oral (%):
- 100
- Absorption rate - dermal (%):
- 39.8
- Absorption rate - inhalation (%):
- 100
Additional information
Doan et al. (2010) investigated the dermal absorption of farnesol in Hartley guinea pigs in vivo using radiolabelled material and in vitro by mounting skin grafts in diffusion cells and measuring receptor fluid fractions. Comparable in vitro and in vivo dermal absorption of farnesol was observed. The in vivo absorption of farnesol led to systematic absorption of 39.8±2.5 % of the applied dose (AD) (mean ± SEM). At 24-hours, 21±0.2 % AD of farnesol remained in the skin and 5.0±2.2 %AD was extracted from carbon impregnated filter papers. The total recovery (mass balance) corresponded only to 65.9 ± 6%.
In vitro farnesol absorption studies suggested penetration of 69.9±4.3 %AD. Extended 72-hour studies found 77.5±4.7 %AD in the receptor fluid with 8.0±1.9 %AD remaining in the skin. The total 72-hour in vitro penetration of farnesol was calculated to be 85.5±6.7 %AD. Under the experimental conditions stated, farnesol is readily absorbed and systemically distributed. The systemic in vivo absorption value coincided with the 24 -hour in vitro absorption value. However, an evaporation test for 3H-Farnesol suggested that there is a potential for evaporative loss. This study is considered to be reliable without restriction (Klimisch 1) as it was a published study with adequate experimental design and sufficient reporting.
Horn et al. (2005) investigated the levels of farnesol in plasma in a study conducted similar to an OECD 407 28-day oral repeated dose toxicity study. Male and female rats received daily exposure to farnesol at doses of 500 or 1000 mg/kg/day by oral gavage, alongside a vehicle control, for 28 days followed by a 28-day recovery period. Total plasma farnesol levels and plasma levels of individual farnesol isomers were analysed at approximately two hours post-dosing during the final week of farnesol administration. Plasma levels of total farnesol (all isomers) and individual farnesol isomers increased with increasing farnesol dose. However, these plasma levels are probably confounded by the fact that farnesol is an endogenous compound which is rapidly metabolised and may be sequestered by intracellular and extracellular binding proteins. In the absence of elimination data, the actual quantification of absorption cannot be performed. However, dermal absorption has been determined at 85.5% and it can be considered that absorption from oral exposure would exceed this level. Consequently, the absorption rate for the oral route is estimated at 100%. This study is considered to be reliable with restriction (Klimisch 2) as it was a published study with minor limitations in reporting.
There are no data covering the kinetics of inhalation exposure so the default of 100% absorption by this route is given.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.